scholarly journals A Rare Case of Metastatic Lung Cancer that Needed to be Differentiated from Inflammatory Breast Cancer

2015 ◽  
Vol 76 (11) ◽  
pp. 2654-2659
Author(s):  
Kazuki HASHIMOTO ◽  
Eri HOHOKABE ◽  
Yuichiro KIKAWA ◽  
Ryosuke MATSUOKA ◽  
Yukihiro IMAI
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Inflammatory Breast Cancer ◽  
Rare Case ◽  
Metastatic Lung Cancer ◽  
Metastatic Lung

scholarly journals Severe Hyperkalemia and Bilateral Adrenal Metastasis

2009 ◽  
Vol 2009 ◽  
pp. 1-2 ◽  
Author(s):  
Michael Nagler ◽  
Beat Müller ◽  
Verena Briner ◽  
Ralph Winterhalder
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Clinical Symptoms ◽  
Adrenal Metastasis ◽  
Common Finding ◽  
Metastatic Lung Cancer ◽  
Adrenal Metastases ◽  
Metastatic Lung ◽  
Severe Hyperkalemia

Adrenal metastases are a common finding in metastatic lung and breast cancer. Often there are no clinical symptoms suggesting them. In this paper, we present a case of a 66-year-old man with metastatic lung cancer suffering from severe hyperkaliemia due to hypoaldosteronism as a result of bilateral adrenal metastasis.

Health state utility and toxicities in metastatic lung cancer: A qualitative study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16017-16017
Author(s):  
B. Nafees ◽  
M. Stafford ◽  
S. Bhalla ◽  
J. Watkins
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Stable Disease ◽  
Progressive Disease ◽  
Response To Therapy ◽  
Economic Evaluations ◽  
Health State ◽  
Metastatic Lung Cancer ◽  
Health States ◽  
Metastatic Lung

16017 Background: In metastatic lung cancer, it is expected that quality of life is impacted both by the efficacy and toxicity of therapy. Previous research has reported health states either based on response to therapy or on toxicity, but not in combination. Using methodology applied in breast cancer (Narewska 2005), we developed health state descriptions for advanced non-small cell lung cancer (NSCLC) for use in cost-utility analyses. Methods: An interview discussion and content validation guide was produced based on literature review and clinical input. Response to therapy was described as responding disease, stable disease, or progressive disease. The most common toxicities were selected based on randomized clinical trials. Descriptions of health states were reviewed by clinical specialists. Final health states will be piloted and then used in a societal-based valuation study using standard gamble technique. The contributory effect of disease state and toxicity will be estimated using a mixed model analysis and compared with the data from the previous breast cancer utility study. Results: Eight toxicities were identified: alopecia and grade 3/4 neutropenia, febrile neutropenia, hand-foot syndrome, gastrointestinal (diarrhea/vomiting), rash, stomatitis and fatigue. These were combined with response to therapy to yield 19 health states: 9 responding disease (one with each toxicity plus one with no toxicity), 9 stable disease (one with each toxicity plus one with no toxicity) and one progressive disease (toxicity not included). These health states were reviewed by 6 pulmonary oncologists and 3 specialist nurses. Conclusions: Development of health states that combine both efficacy and toxicity will be useful in evaluating the relative value of therapies for advanced NSCLC and comparison with other diseases. Input by clinical experts has provided validation for the proposed health states. Evaluation of these health states by members of society will provide appropriate perspective for economic evaluations. [Table: see text]

Efficacy of electroacupuncture for bone metastatic cancer patients with neuropathic pain: A randomized controlled trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9534-9534 ◽  
Author(s):  
L. Sima ◽  
C. Yin
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Neuropathic Pain ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Metastatic Cancer ◽  
Metastatic Lung Cancer ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Metastatic Lung

9534 Background: Bone metastatic lung cancer or breast cancer pts often have neuropathic pain which has poor reaction to opioids. A clinical trial is to investigate efficacy of electroacupuncture (EA) in cancer pts with neuropathic pain. Methods: Inclusion criteria were: bone metastatic lung cancer or breast cancer pts at least one of the symptoms as burning pain, shooting pain, dysesthesias, or allodynia; numerical rating scale (NRS) of pain intensity >=4.0; stable dose of opioids for at least 72 hours. Exclusion criteria were: chemotherapy or radiotherapy from 15 days before or during the study. Hormone or adjuvant therapy could be started before the study, but the dose could not be changed afterwards. Opioids could be increased step by step according to the pain. EA was manipulated with low-frequency (2 Hz) and high-frequency (100 Hz) dense-disperse waves alternatively, 30 minutes per day, 5-day therapy with 2-day interval, 3 weeks continuously. Acupoints were selected as ST36, SJ3, SJ5, LI3, LI4 bilateral. Controlled group accepted non-acupoint treatment close the right acupoint. Results: Ninety pts with neuropathic pain participated in a randomized, controlled design trial from 2006 to 2008. Overall, 45 pts accepted EA treatment and 34 completed the study. 45 pts accepted controlled and 32 completed. There was no difference of initial NRS which was 6.3±2.1 in EA group and 7.2±1.8 in controlled, p = 0.0669. Analysis showed a significant difference of NRS between EA group (3.2±1.7) and controlled (5.4±2.2) at the end of survey, p < 0.0001. The decrease in NRS was significantly higher in the EA group compared to the controlled (3.2±1.7 vs. baseline, p < 0.0001; 5.4±2.2 vs. baseline, p = 0.0007). Mean analgesics consumption variety in EA group was as follows: transdermal fentanyl increased by 51.2% (16 pts) and 77.3% (21 pts) in EA and controlled, p = 0.0005. Oxycodone increased by 85.5% (18 pts) and 115.6% (11 pts) in EA and controlled, p = 0.0183. Functional Assessment of Cancer Therapy-General (FACT-G) scale had no difference at the beginning, while it were 102±18 and 85±12 in EA group and controlled at the end of survey, p < 0.0001. Conclusions: EA can alleviate neuropathic pain of bone metastatic cancer pts, decrease the analgesics consumption, and promoting quality of life. No significant financial relationships to disclose.

A RARE CASE OF ERDHEIM-CHESTER DISEASE MASQUERADING AS METASTATIC LUNG CANCER

CHEST Journal ◽  
2018 ◽  
Vol 154 (4) ◽  
pp. 649A-650A
Author(s):  
PARIN SHAH ◽  
NAYLA AHMED ◽  
ANIKET SHARMA ◽  
AYUSHI CHAUHAN ◽  
PRASHANT GROVER ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Rare Case ◽  
Metastatic Lung Cancer ◽  
Erdheim Chester Disease ◽  
Metastatic Lung ◽  
Erdheim Chester ◽  
Chester Disease

Sleep Disturbances in Metastatic Lung Cancer

2019 ◽  
Author(s):  
M. Kaous ◽  
D.D. Balachandran ◽  
G. Pacheco ◽  
S.A. Mahoney ◽  
J.N.T. Po ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Sleep Disturbances ◽  
Metastatic Lung Cancer ◽  
Metastatic Lung

scholarly journals Patients with Metastatic Lung Cancer and Oncologists’ Views on Achievement of Treatment Goals and Making the Right Treatment Decision: A Prospective Multicenter Study

2021 ◽  
pp. 0272989X2199895
Author(s):  
Adinda Mieras ◽  
Annemarie Becker-Commissaris ◽  
Hanna T. Klop ◽  
H. Roeline W. Pasman ◽  
Denise de Jong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multicenter Study ◽  
Systemic Treatment ◽  
Treatment Decision ◽  
Treatment Goals ◽  
Metastatic Lung Cancer ◽  
Prospective Multicenter Study ◽  
Cancer Data ◽  
Metastatic Lung ◽  
The Right

Background Previous studies have investigated patients’ treatment goals before starting a treatment for metastatic lung cancer. Data on the evaluation of treatment goals are lacking. Aim To determine if patients with metastatic lung cancer and their oncologists perceive the treatment goals they defined at the start of systemic treatment as achieved after treatment and if in hindsight they believe it was the right decision to start systemic therapy. Design and Participants A prospective multicenter study in 6 hospitals across the Netherlands between 2016 and 2018. Following systemic treatment, 146 patients with metastatic lung cancer and 23 oncologists completed a questionnaire on the achievement of their treatment goals and whether they made the right treatment decision. Additional interviews with 15 patients and 5 oncologists were conducted. Results According to patients and oncologists, treatment goals were achieved in 30% and 37% for ‘quality of life,’ 49% and 41% for ‘life prolongation,’ 26% and 44% for ‘decrease in tumor size,’ and 44% for ‘cure’, respectively. Most patients and oncologists, in hindsight, felt they had made the right decision to start treatment and also if they had not achieved their goals (72% and 93%). This was related to the feeling that they had to do ‘something.’ Conclusions Before deciding on treatment, the treatment options, including their benefits and side effects, and the goals patients have should be discussed. It is key that these discussions include not only systemic treatment but also palliative care as effective options for doing ‘something.’

Sign in / Sign up

Export Citation Format

Share Document